AI-Driven Drug Discovery and Cell & Gene Therapy: The Twin Pillars of Future Medicine

Looking back at the investment landscape of the healthcare market in 2020, the total transaction value exceeded $45 billion throughout the year. Among these, the pharmaceutical and biotechnology sectors were particularly active. As the main battlefield for healthcare investments, there were 2 private equity financing events throughout the year.43 deals, with a total disclosed transaction value reaching $10.7 billion. Innovations in information technologies such as 5G, artificial intelligence, and big data, along with monoclonal antibodies and other large-molecule drugs, RNA-based therapeutics, gene-editing technologies, and cellThe emergence of cutting-edge medical technologies, such as cell therapy, has given rise to a cohort of star companies and investment opportunities. Among these, AI-driven drug R&D and gene and cell therapy have garnered significant industry attention.

Since Shenzhen was designated as one of the first national bio-industry bases by the National Development and Reform Commission in 2005, its bio-industry has experienced rapid growth at an average annual rate of 20%. To date, it has become a fertile ground for nurturing innovative biopharmaceutical enterprises. As Shenzhen’s “Biopharmaceutical Industry Innovation Leading Zone,” Nanshan District concentrates 80% of the city’s higher education institutions and R&D organizations specializing in biopharmaceuticals, and is home to three Nobel laureate laboratories in the biopharmaceutical field, including the Edvard Moser Laboratory for Neural Plasticity.It has gathered approximately 167 innovation carriers, including key laboratories, engineering centers, and public technical service platforms, among which 11 are national-level innovation carriers. With a relatively complete closed-loop industrial chain, it has cultivated a group of industry-leading enterprises such as Mindray Medical, Joincare Pharmaceutical, Chipscreen Biosciences, and Lifetech Scientific, forming a cluster of leading enterprises and innovative enterprises.development pattern of aggregation.

Seizing the significant historical opportunities presented by the “Dual-Zone” drive and the comprehensive reform pilot program, the Shenzhen Municipal Government and the Nanshan District Government have successively rolled out a series of policies to foster the development of the biopharmaceutical industry, further promoting its high-quality growth. To align with the prevailing theme of innovation in the era and grasp future trends in healthcare development, the event, guided by the People’s Government of Nanshan District, hosted by the Nanshan District Science and Technology Innovation Bureau, and organized by VCBeat, “2021 Future Healthcare Technology Trends ForumWill be held in Shenzhen·Nanshan on October 14.

This conference, themed “DeepForce” as its theme, focusing on the application of cutting-edge technological innovations and anchoring the development of the biopharmaceutical industry ecosystem. It gathers national academicians, industry leaders, top-tier investors, and core resources from the medical technology innovation ecosystem, aiming to build a global platform for sharing frontier technologies in the future healthcare industry, connecting industrial resources, facilitating industry exchange and cooperation, and releasing trends in future healthcare, thereby constructing “Service-Led + Innovation-Driven + Enterprise-Centric + High-End Agglomeration” innovative ecosystem, thereby propelling the Nanshan District’s biopharmaceutical industry to take a leading role in its development.

Click the image to register for the conference.

This conference aims to create a multi-party resource linkage platform for government, industry, academia, research, medical practice, and investment in the global healthcare industry, as well as a platform for sharing cutting-edge technologies, releasing future medical trends, and facilitating industry exchange and cooperation. Several key highlights are worth anticipating:

This conference will specially invite academicians from the national academy in the pharmaceutical and medical fields to attend, sharing new achievements and emerging trends in the future development of medical technology. Additionally, it will feature on-site presentations by renowned experts, seasoned investors, executives from multinational and publicly listed companies, leading industry enterprises, and prominent players in high-growth niche sectors.

Focusing on two hot sub-sectors—AI-driven drug discovery and cell and gene therapy (CGT)—how does biocomputing empower the pharmaceutical industry ecosystem? How will AI-driven drug discovery expand its scope? How can a closed-loop value chain for cell therapy be established? What is the transformation roadmap for the healthcare industry over the next five years? The conference will invite industry luminaries and representatives from leading enterprises to provide insights on these questions.

The 2021 Biopharmaceutical Value Sector Ranking is part of the Future Healthcare Top 100 · Value Sector Rankings series. By conducting a comprehensive multi-dimensional analysis of candidate companies across factors such as R&D teams, R&D investment, technological capabilities, progress of products in development, market potential, and performance of launched products, this ranking identifies the leading enterprises in the biopharmaceutical value sector for 2021, focusing on two currently prominent sub-sectors: cell and gene therapy, and AI-driven drug discovery and development.

(Registration link:http://vcbeat-vb100.mikecrm.com/joqz0L4）

As the “Innovation Leadership Zone” of Shenzhen’s biomedical industry, Nanshan District boasts numerous universities and research institutions, outstanding original innovation capabilities, and a superior business environment. According to relevant statistical data, in 2020, the output value of the biomedical industry in Nanshan District accounted for approximately one-third of Shenzhen’s total citywide output, underscoring its solid industrial foundation. At the conference, representatives from the Nanshan District Government will provide an authoritative interpretation of the district’s biomedical business environment, offering direction and guidance for the establishment of benchmark enterprises in specialized sectors and the incubation of innovative projects.

How to navigate the surging wave of capital? How to strategically position yourself in frontier medical technology innovation? What new landscape will emerge from the integration of cutting-edge technologies and the healthcare sector? Join us at this conference to explore the answers. On October 14, in Nanshan, Shenzhen, we look forward to meeting you.

Conference Date: October 14, 2021 (Thursday) 9:00-17:00

Venue: Shenzhen Talent Academy, Nanshan, Shenzhen

Registration Link:http://hdxu.cn/pgfQW